Looks like the market is about to get squeezed down below the breakout zone. It will probably stop anywhere from $200 to $210 next. We have a large downward channel acting as the top of a descending triangle that will take us to the low $200s. We had a failed H&S that took us to $245 where we were stopped by the lower end of the breakout zone before the big...
40% short interest 30+ days to cover, and several buy signals shaping up. Bullish MACD Cross, Stochastics, and breaking out of a steep downtrend. New 3 month closing highs after retaking both the 50 day and 200 day moving averages this week. Weekly PAR SAR just printed bullish as well. Would jump in or add on the break of $7.50. On a fundamental basis they...
For detailed commentary and analysis, see our blog post published 10/3/14: www.syncubate.com In this post, we'll dissect the stock's surreal run up from the low $50s in the beginning of September to its near-term high of $96.45 on 9/30/14. Our chart as published on our blog represents two time frames of interest to us from a price action standpoint. The first...
Continuing coverage of ACRX this week, we saw ACRX pullback with the market as a whole early this morning. ACRX broke right through support at the .236 retrace, but found support at yesterdays congested zone at the .382 retrace. Uptrend remains in place. $9 remains 1st target. Stop now at 7.70.
Posted a chart on ACRX earlier in the day as a possible short squeeze. ACRX rallied 4% since the posting. Please refer to my earlier chart for analysis.
After getting hammered in July from the FDA delaying approval on its' latest drug for pain relief, Bears have been piling on making an incredible 20% of the float short. Recent buy ratings from analysts could be the catalyst to get a short squeeze going to begin filling the gap left from the huge 40%+ drop in July. If momentum can carry the stock past 8, then 9...